Category Archives: Other

Seq’ing Clarity from the Horizon – EloraTZP vs. Zenagamtide

Just when you think Lilly has reached the ceiling, it breaks through again with a new high-efficacy AOM offering, EloraTZP. For context, Lilly shared data from its Ph2 EloraTZP (eloralintide + tirzepatide; QW SC SARA + GLP-1/GIP dual agonist) study at EASD 2026 yesterday, demonstrating robust weight loss and glycemic control among an obese + T2DM population (previous FENIX insight). This prompted FENIX to consider the potential future showdown between EloraTZP and Novo’s combination successors: cagrisema and zenagamtide. Further, it should be noted that while the EloraTZP data are largely seen as another win under Lilly’s belt, its stock dropped ~2% after the readout.

This content is for Read Less members only.

Already a member? Log in here

EASD 2026 Key Press Releases (September 30 Part 2)

On the third day of EASD 2026, four key news items were observed in the afternoon from Lilly, AbbVie, Kailera Therapeutics, and Insilico Medicine. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.

Already a member? Log in here

TRIUMPH-5 is All Triumph

With the full results presentation of TRIUMPH-2 for Lilly’s retatrutide today at EASD 2026 (previous FENIX insight), the FENIX team was debating the utility of conducting TRIUMPH-5. Recall, Lilly’s own H2H trial of retatrutide vs. tirzepatide in weight management popped up on CT.gov in Oct 2024 and has topline results projected in Q1 ’27, maybe around JPM week or earnings in late January. Interestingly, the FENIX team’s clarity at breakfast changed after the TRIUMPH-2 results presentation this morning. We pull back the curtain below.

This content is for Read Less members only.

Already a member? Log in here

EASD 2026 Key Press Releases (September 30)

On the third day of EASD 2026, four key news items were observed from Lilly, Zealand Pharma, Novo/Ro, and NewAmsterdam Pharma. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.

Already a member? Log in here

EASD 2026 Key Press Releases (September 29)

On the second day of EASD 2026, seven key news items were observed from Novo/Hengrui, Lilly, Caspian Therapeutics, Merck/Cyprumed GmbH, and Oura. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.

Already a member? Log in here

EASD 2026 Key Press Releases (September 28)

On the first day of EASD 2026, six key news items were observed from Roche, Tandem Diabetes Care, Dexcom, Lilly, MindRank, and DreaMed Diabetes. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.

Already a member? Log in here

Negative Nancy: Novo 2026 Capital Markets Day Highlights and Analysis Part 3

Part 3 of FENIX’s 2026 Novo CMD coverage recaps the company’s strategy to navigate and grow through the eventual sema LOE, arguably the biggest headwind in the company’s 100+ year history. Below, FENIX outlines several key factors that could influence Novo’s ability to navigate the difficult period, including the speculative hypothesis that Lilly gets to decide whether Novo will pursue generic tirzepatide.

This content is for Read Less members only.

Already a member? Log in here

EASD 2026 Preview: Where FENIX will be paying attention and why

With EASD 2026 approaching (September 28-October 2; Milan, Italy), FENIX has compiled a short list of key sessions and presentations that warrant close attention. While EASD brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately have an outsized impact on the field for years to come.

This content is for Read Less members only.

Already a member? Log in here

Novo Partners for Q3M AOMs; Clywedog Announces Ph1b T2DM Data

Two cardiometabolic-related news items have been observed: Novo partnered with Nanexa to develop up to five ultra-long-acting obesity/T2DM assets (view press release), and Clywedog Therapeutics announced Ph1b data for its menin inhibitor in T2DM (view press release). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here

Onswik FDA Approval; Lilly Medicare GLP-1 Bridge Program Market Share; BI + WHO Global Metabolic Health Collaboration; Roche + Atavistik Partner for Allosteric Drug Discovery; Aqua Medical T2DM Endoscopic Procedure; Biolinq Shine OTC FDA Clearance; Rezera RESOLVE-1 AHA Presentation

A series of cardiometabolic-related news items has been observed from Lilly, BI/WHO, Roche/Atavistik Bio, Aqua Medical, Biolinq, and Rezera. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.

Already a member? Log in here